Industrialized CRISPR iPS Cells Enable NIH Large Scale Alzheimer’s Disease Research Effort
Advancing Neurodegenerative Research with High-Throughput CRISPR Editing
Alzheimer’s disease and related dementias (ADRD) are progressive neurodegenerative disorders affecting over 6 million people in the United States—a number projected to nearly triple by 2050 due to an aging population. Globally, ADRD impacts more than 55 million individuals, with a new case developing every three seconds. This surge presents a looming public health crisis, with annual care costs expected to reach $1.1 trillion in the U.S. alone by 2050.
Learn more in this Editorial: Combating Alzheimer’s Disease with CRISPR: A Step Forward Towards New Therapeutics.
EditCo partnered with the National Institutes of Health (NIH) on the iPSC Neurodegenerative Disease Initiative (iNDI) project. The iNDI project aims to accelerate neurodegenerative disease research by creating a publicly available, comprehensive library of CRISPR-engineered iPS cell lines representing various genetic mutations associated with ADRD.
EditCo's Contributions:
- Industrialized CRISPR Editing Platform: Leveraging our high-throughput CRISPR editing capabilities, we efficiently generated a large number of precisely edited iPS cell lines required for the iNDI project.
- Expertise in iPS Cell Editing: Our proprietary protocols ensured high-efficiency gene edits while maintaining cell viability and pluripotency, crucial for downstream differentiation into neurons.
- Quality and Precision: Utilizing state-of-the-art reagents and rigorous quality control processes, we delivered iPS cell lines with accurate gene edits.
